2. Search Result
Search Result
Results for "

nanobody

" in MedChemExpress (MCE) Product Catalog:

13

Inhibitors & Agonists

1

Biochemical Assay Reagents

10

Inhibitory Antibodies

45

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99227
    Caplacizumab (His Tag)
    1 Publications Verification

    ALX-0681; ALX-0081

    		 Integrin Transmembrane Glycoprotein Cardiovascular Disease
    Caplacizumab (His Tag) is a humanized anti-von Willebrand factor (vWF) nanobody. Caplacizumab (His Tag) inhibits the binding of vWF with platelet glycoprotein (GP) Ibα. Caplacizumab (His Tag) inhibits the vWF-mediated platelet adhesion and prevents further microthrombi formation. Caplacizumab (His Tag) can be used for the research of thrombotic thrombocytopenic purpura (TTP) .
    Caplacizumab (His Tag)
  • HY-P99796
    Ozoralizumab

    ATN-103; PF-5230896

    		 TNF Receptor Inflammation/Immunology
    Ozoralizumab (ATN-103) is an anti-TNFα humanized antibody. Ozoralizumab is a humanized trivalent nanobody compound that consists of two anti-human TNFα nanobodies and an anti-human serum albumin (HSA) nanobody. Ozoralizumab can be used in research of arthritis .
    Ozoralizumab
  • HY-W087027
    Maleimide-NOTA

    		Radionuclide-Drug Conjugates (RDCs) Biochemical Assay Reagents Integrin Cancer
    Maleimide-NOTA is a chelate. Maleimide-NOTA can be site-specifically coupled to the hPD-L1 nanobody bearing the Cys-tag. Maleimide-NOTA can specifically conjugate to A20FMDV2 (HY-P1654). The [ 68Ga]Ac-CG6 formed by the conjugation of 68Ga radiolabeled Maleimide-NOTA with A20FMDV2 can be used for PET imaging of αvβ6 integrin-positive pancreatic ductal adenocarcinoma .
    Maleimide-NOTA
  • HY-112624A
    Dextran T1 (MW 1,000)

    Dextran 1; Dextran D1; Dextran T1(MW 800-1200)

    		 Biochemical Assay Reagents Others
    Dextran T1 (Dextran 1; Dextran D1) (with a molecular weight of 1,000) is a dehydrated glucose polymer with an average molecular weight of 1,000. Dextran T1 (MW 1,000) has excellent biodegradability and biocompatibility, and can be used as a nanobody carrier scaffold and a freeze-drying protectant. Dextran T1 (MW 1,000) promotes the retention of circulating tumor cells in the capillary bed .
    Dextran T1 (MW 1,000)
  • HY-P99397
    Sonelokimab

    ALX 0761; M 1095

    		 Interleukin Related MMP Inflammation/Immunology
    Sonelokimab (ALX 0761) is a trivalent bispecific nanobody composed of camel derived humanized IL-17F antibodies, IL-17A/F antibodies, and serum albumin VHH antibodies. Sonelokimab can prolong the plasma half-life by binding to human serum albumin. Sonelokimab can be used for research on rheumatoid arthritis and psoriasis .
    Sonelokimab
  • HY-P99647
    Gontivimab

    ALX-0171; VR-465

    		 RSV Infection
    Gontivimab (ALX-0171; VR-465) is a poent anti-RSV prefusion F protein nanobody with a KD value of 0.113 nM. Gontivimab shows antiviral activity. Gontivimab reduces the RSV load in the nose and lung .
    Gontivimab
  • HY-P990907
    Brivekimig

    F-027300252; SAR-442970

    		 TNF Receptor Inflammation/Immunology
    Brivekimig (F-027300252; SAR-442970) is a bispecific nanobody targeting TNF/OX40L. Brivekimig is applicable to research related to hidradenitis suppurativa.
    Brivekimig
  • HY-P991725
    Velvakiment

    ZL-1102

    		 Interleukin Related Inflammation/Immunology
    Velvakiment is a humanized VHH nanobody that targets IL-17A. Velvakiment can be used for autoimmune diseases such as multiple sclerosis and rheumatoid arthritis research .
    Velvakiment
  • HY-P991866
    BI 1034020

    		Amyloid-β Neurological Disease
    BI 1034020 is a humanized nanobody, targeting two different epitopes of Aβ ( Aβ40 and Aβ42) with high affinity. BI 1034020 reduces the level of free Ab peptide in plasma and thus prevent the formation of new Aβ plaques and clear existing plaques. BI 1034020 can be used for Alzheimer’s disease research .
    BI 1034020
  • HY-P992457
    SAR444200

    		Glycoprotein VI Interleukin Related Cancer
    SAR444200 is a nanobody T-cell engager targeting GPC3 (glypican-3) and TCRαβ (T-cell receptor αβ). SAR444200 has a KD of 0.023 nM for human GPC3 and a KD of 5.2 nM for human TCRαβ. SAR444200 mediates T-cell-dependent cytotoxicity, with high selectivity and killing activity against GPC3-positive tumor cells. SAR444200 binds to GPC3 in a dual-epitope manner, and binds to TCRαβ via its N-terminal nanobody, forming an artificial immunological synapse between T cells and tumor cells. SAR444200 can be used for the research of GPC3 + solid tumors, including liver cancer, lung squamous cell carcinoma and melanoma .
    SAR444200
  • HY-P992473
    TAS266

    		TNF Receptor Inflammation/Immunology Cancer
    TAS266 is a tetrameric nanobody agonist targeting DR5. TAS266 selectively induces cancer cell death. TAS266 triggers sustained tumor regression in xenograft models and also elicits immunogenic responses including antibody binding. TAS266 exhibits superior anti-tumor efficacy compared with traditional DR5-targeting strategies. TAS266 can be used in research related to pancreatic cancer and advanced solid tumors .
    TAS266
  • HY-P992323
    BI-836880

    		VEGFR Tie ERK Cardiovascular Disease Cancer
    BI-836880 is a humanized bispecific nanobody and a selective inhibitor of VEGF and ANG2, with a Kd of 16 pM for hANG2, an EC50 of 1.4 nM for VEGF165, and an EC50 of 2.3 nM for VEGF121. BI-836880 blocks ERK phosphorylation downstream of VEGF-A as well as TIE2 phosphorylation downstream of ANG2. BI-836880 does not inhibit ANG1-mediated TIE2 phosphorylation. BI-836880 exerts anti-angiogenic effects, reduces the number of immature endothelial vessels in tumor tissues, and inhibits tumor growth in preclinical models. BI-836880 can be used in the research of pancreatic cancer, non-small cell lung cancer, renal cell carcinoma, ovarian cancer, colon cancer, and Lewis lung cancer .
    BI-836880
  • HY-178271
    P-SCN-Bn-NOTA

    		Drug Intermediate Cancer
    P-SCN-Bn-NOTA is a metal chelator and molecular imaging probe precursor that allows radiolabeling with Ga-68. P-SCN-Bn-NOTA can be conjugated to CD70-specific molecules B3, B6, ABDB3 and ABDB6 to form NOTA-labeled derivatives. P-SCN-Bn-NOTA is applicable for preclinical PET/CT imaging of CD70-expressing tumors in NCG mouse PDX models. P-SCN-Bn-NOTA can be used in studies related to CD70-positive tumors .
    P-SCN-Bn-NOTA

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: